Merck Canada Sues To Block Mylan's Generic Singulair

Law360, New York (January 3, 2012, 1:15 PM EST) -- Merck Canada Inc. on Thursday sued Mylan Pharmaceuticals Inc. in New Jersey federal court for allegedly infringing a Merck patent when it sought U.S. Food and Drug Administration approval for a generic version of the asthma treatment Singulair.

The plaintiffs — Merck Canada, Merck Frosst Canada & Co. and Merck Sharp & Dohme Pharmaceuticals — say Mylan alerted them in a Nov. 15 letter that it had lodged an abbreviated new drug application seeking a green light to make and sell its generic.

Mylan also informed...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.